EUVIMEDEUVIMED entdecken
Leitlinie

2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

Mary Beth Humphrey, Linda Russell, Maria I Danila iD, Howard A Fink, Gordon Guyatt, Michael Cannon, Liron Caplan iD, Sara Gore, Jennifer Grossman, Karen E Hansen, Nancy E Lane, Nina S Ma und 20 weitere

Arthritis Care & Research · 2023-12 · 75 (12) · 2405-2419

DOI: 10.1002/acr.25240 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Arthritis Care & Research, online erschienen am 26.10.2023. Verfasst von Mary Beth Humphrey und 31 weiteren Autor:innen. Beteiligte Einrichtung: University of Oklahoma Health Sciences Center and U.S. Department of Veterans Affairs, Oklahoma City, Oklahoma. Hauptthemen laut MEDLINE: Osteoporosis, Rheumatology. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective is to update recommendations for prevention and treatment of glucocorticoid‐induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.

Methods

An updated systematic literature review was performed for clinical questions on nonpharmacologic, pharmacologic treatments, discontinuation of medications, and sequential therapy. Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the certainty of evidence. A Voting Panel achieved ≥70% consensus on the direction (for or against) and strength (strong or conditional) of recommendations.

Results

For adults beginning or continuing >3 months of GC treatment, we strongly recommend as soon as possible after initiation of GCs, initial assessment of fracture risks with clinical fracture assessment, bone mineral density with vertebral fracture assessment or spinal x‐ray, and Fracture Risk Assessment Tool if ≥40 years old. For adults at medium, high, or very high fracture risk, we strongly recommend pharmacologic treatment. Choice of oral or intravenous bisphosphonates, denosumab, or parathyroid hormone analogs should be made by shared decision‐making. Anabolic agents are conditionally recommended as initial therapy for those with high and very high fracture risk. Recommendations are made for special populations, including children, people with organ transplants, people who may become pregnant, and people receiving very high‐dose GC treatment. New recommendations for both discontinuation of osteoporosis therapy and sequential therapies are included.

Conclusion

This guideline provides direction for clinicians and patients making treatment decisions for management of GIOP. These recommendations should not be used to limit or deny access to therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisRheumatologyAdultChildHumansBone DensityGlucocorticoidsUnited StatesSystematic Reviews as Topic

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • University of Oklahoma Health Sciences Center and U.S. Department of Veterans Affairs, Oklahoma City, Oklahoma.
  • Hospital for Special Surgery, New York, New York.
  • University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, Alabama.
  • Geriatric Research Education and Clinical Center, VA Health Care System, Minneapolis, Minnesota.
  • McMaster University, Hamilton, Ontario, Canada.
  • Arthritis Consultants of Tidewater, Virginia Beach, Virginia.

ORCID-Profile: Maria I Danila, Liron Caplan, Marina Magrey, Lesley Jackson, Katherine Wysham, Amy S Turner

Zitieren

APA

Humphrey, M. B., Russell, L., Danila, M. I., Fink, H. A., Guyatt, G., Cannon, M., Caplan, L., Gore, S., Grossman, J., Hansen, K. E., Lane, N. E., Ma, N. S., Magrey, M., McAlindon, T., Robinson, A. B., Saha, S., Womack, C., Abdulhadi, B., Charles, J. F., …, & Uhl, S. (2023). 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis Care & Research, 75(12), 2405-2419. https://doi.org/10.1002/acr.25240

Vancouver

Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis Care & Research. 2023;75(12):2405-2419. doi:10.1002/acr.25240

BibTeX
@article{Humphrey2023,
  author = {Humphrey, Mary Beth and Russell, Linda and Danila, Maria I and Fink, Howard A and Guyatt, Gordon and Cannon, Michael and Caplan, Liron and Gore, Sara and Grossman, Jennifer and Hansen, Karen E and Lane, Nancy E and Ma, Nina S and Magrey, Marina and McAlindon, Tim and Robinson, Angela Byun and Saha, Sumona and Womack, Charles and Abdulhadi, Basma and Charles, Julia F and Cheah, Jonathan T L and Chou, Sharon and Goyal, Itivrita and Haseltine, Katherine and Jackson, Lesley and Mirza, Reza and Moledina, Iram and Punni, Emma and Rinden, Tim and Turgunbaev, Marat and Wysham, Katherine and Turner, Amy S and Uhl, Stacey},
  title = {2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis},
  journal = {Arthritis Care & Research},
  year = {2023},
  volume = {75},
  number = {12},
  pages = {2405--2419},
  doi = {10.1002/acr.25240}
}
Kostenlos starten →